The Kitasato Institute

Kyowa Hakko Kogyo Kabushiki Kaisha

Nihon Tokushu Noyaku Seizo Kabushiki Kaisha

The Kiyasato Institute

Nihon Tokushu Moyaku Seizo Kabushiki Kaisha

The Kitasato Institute (kitasato Kenkyuosho)

The Kitasato Institute (kitasato Kenkyusho)

Juichi Awaya

Satoshi Omura

Haruo Tanaka

Toju Hata

Ruiko Oiwa

Michiko Katagiri

Haruko Terada

Shizuo Higashikawa

Kazuomi Yasui

Shimpei Kuyama

Akira Nakagawa

Yuzuru Iwai

Kanki Komiyama

Yoko Takahashi

Iwao Umezawa

Masayuki Onda

Yaeko Konda

Chiaki Kitao

Keiki Satoh

Yoshitsugu Narimatsu

The present invention relates to new compound nanaomycin A and derivatives thereof represented by general formula: ##STR1## in which (a) R is H and R' is OH (nanaomycin A),

Compound nanaomycin A and derivatives thereof and a process for

The present invention relates to new compound designated as nanaomycin B represented by general formula: ##STR1## Nanaomycin B is a quinone type and is active on mycoplasma, Gram-positive bacteria and trycophyton. This compound is useful as a medicament for infectious diseases of humans and animals caused by a parasite of trichophyton or mycoplasma etc. The acute toxicity (LD.sub.50, intra-penetrial injection) in mice of this compound is 169 mg/Kg. Nanaomycin B is produced by fermentation in which a nanaomycin-producing strain belonging to the genus Streptomyces is cultured in a medium under aerobic conditions and the accumulated nanaomycin B in the cultured broths is recovered therefrom.

Nanaomycin B and therapeutic compositions containing same

The present invention relates to a new composition designated as AM-1042 or asukamycin. AM-1042 has an antibiotic activity upon Gram-positive bacteria and Eimeria, and its acute toxicity (LD.sub.50 ' ip.) in mice was 48.5 mg./kg. AM-1042 has an excellent therapeutical effect on various infectious diseases caused by a parasite of Gram-positive bacteria and Eimeria. AM-1042 has been confirmed to be distinguishable from known antibiotics such as e.g. amicetin B, azomycin and manumycin. AM-1042 is produced by fermentation of a microorganism belonging to the genus Streptomyces and capable of producing AM-1042. A composition capable of preventing and curing coccidiosis of poultry containing AM-1042 as active ingredient.

Antibiotic composition

A novel compound frenolicin B of the formula: ##STR1## is prepared by cultivating a microorganism belonging to genus Streptomyces, e.g. Streptomyces roseofulvus AM-3867, in a culture medium and isolating the compound formed and accumulated in the medium from the cultured product. Said frenolicin B is useful as an antibiotic.

Compound, frenolicin B which is useful as an antibiotic

Production of nanaomycin A and derivatives thereof

The present invention relates to new compound designated as nanaomycin B represented by general formula: ##STR1## Nanaomycin B is a quinone type and is active on mycoplasma, Gram-positive bacteria and trycophyton. This compound is useful as a medicament for infectious diseases of humans and animals caused by a parasite of trichophyton or mycoplasma etc. The acute toxicity (LD.sub.50, intra-penetrial injection) in mice of this compound is 169 mg/kg. Nanaomycin B is produced by fermentation in which a nanaomycin-producing strain belonging to the genus Streptomyces is cultured in a medium under aerobic conditions and the accumulated nanaomycin B in the cultured broths is recovered therefrom.

Production of nanaomycin B

The present invention relates to a new antibiotic designated as OS-3256-B. OS-3256-B exhibits excellent inhibitory activities against animal tumors such as leukemia L-1210, Sarcoma-180 and Hela cells and gram-positive bacteria and is classified into the diazocompounds group. However, chromatographic analysis, Rf value and other experimental data reveal that OS-3256-B is a new compound of the type of azaamino acid derivatives. The present invention also provides a process for producing OS-3256-B by fermentation, in which OS-3256-B is produced by culturing a microorganism belonging to Streptomyces candidus var. azaticus in a culture medium conventionally used for culturing Streptomyces strain microorganisms.

Antibiotic OS-3256-B

This invention relates to a new compound NA-337 and a process for producing the same by fermentation. NA-337 is positive in Dragendorff's reagent. NA-337 is confirmed to be a new compound having a fat-clearing activity. This compound is produced by fermentation, in which an NA-337-producing strain is cultured aerobically in a medium and the accumulated NA-337 is recovered from the cultured matters.

Compound NA-337 and a process for producing the same by fermentation

The antifungal antibiotic substance 'F-1028' having the following formula, ##EQU1## or an acid salt thereof, a process for the production of the same by fermentation, and a fungicidal composition useful for agricultural and horticultural use.

Novel antifugal antibiotic substance, process for production of the

Novel antifungal antibiotic substance, and agricultural and

Growing community of inventors

Souka, Japan

Juichi Awaya